SIMCERE PHARMA (02096) announced its 2025 financial results, achieving revenue of 7.731 billion yuan, representing a 16.5% year-on-year increase. Revenue from innovative drug operations reached 6.304 billion yuan, accounting for 81.5% of total revenue and growing 27.9% compared to 2024. Profit attributable to equity shareholders of the company was 1.344 billion yuan, up 86.2% year-on-year. Adjusted profit attributable to equity shareholders stood at 1.280 billion yuan, an increase of 27.1%. Earnings per share were 0.54 yuan, with a final dividend of 0.18 yuan per share.
The company attributed the revenue growth primarily to increased income from innovative drugs and licensing agreements. The rise in profit was driven by higher innovative drug revenue, licensing income, and net gains from the fair value of the group's investment portfolio.
In 2025, the group maintained its strategic focus on "greater efficacy and differentiation," achieving high-quality growth. The innovative drug business accelerated, with the number of commercialized innovative drugs expanding to ten, contributing to record revenue and an increasing share of total income. Within its key therapeutic areas, the group has built a pipeline of over 60 innovative drugs, supported by an efficient clinical and regulatory team that continues to advance global research and development and accelerate the translation of innovative results.
The group also made positive progress in international collaboration and out-licensing of its self-developed pipeline, further expanding the global footprint of its innovative medicines. Ten innovative drugs have been approved for market sale within its focused areas. As of December 31, 2025, 14 of the group's products have been included in guidelines and pathways issued by more than 100 government bodies or authoritative professional societies, and over 45 products have been included in the National Reimbursement Drug List (NRDL).
Comments